Novo Nordisk expands US patient access to FDA-approved semaglutide medicines through Hims & Hers in response to a shift in their US GLP-1 business model

FDA approves Novo Nordisk's Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access